|
AU698393B2
(en)
|
1994-06-24 |
1998-10-29 |
Immunex Corporation |
Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
|
|
IL112834A
(en)
|
1995-03-01 |
2000-12-06 |
Yeda Res & Dev |
Pharmaceutical compositions for controlled release of soluble receptors
|
|
US6020004A
(en)
|
1997-04-17 |
2000-02-01 |
Amgen Inc. |
Biodegradable microparticles for the sustained delivery of therapeutic drugs
|
|
US6541606B2
(en)
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
|
US6432449B1
(en)
|
1998-05-18 |
2002-08-13 |
Amgen Inc. |
Biodegradable sustained-release alginate gels
|
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
|
US6451346B1
(en)
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
|
EP1345968A2
(en)
*
|
2000-12-28 |
2003-09-24 |
Altus Biologics Inc. |
Crystals of whole antibodies and fragments thereof and methods for making and using them
|
|
US8821086B2
(en)
*
|
2006-12-22 |
2014-09-02 |
Tennine Corporation |
Method and apparatus for controlled-fracture machining
|
|
WO2008109871A2
(en)
*
|
2007-03-08 |
2008-09-12 |
Irm Llc |
Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
|
|
AR066042A1
(es)
*
|
2007-04-13 |
2009-07-22 |
Novartis Ag |
Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
|
|
JOP20080381B1
(ar)
*
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
US20130072665A1
(en)
*
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
|
EP2296694B1
(en)
*
|
2008-04-23 |
2015-08-05 |
Amgen Inc. |
Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
|
|
KR100985090B1
(ko)
*
|
2008-05-23 |
2010-10-04 |
한국과학기술연구원 |
크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
|
|
WO2011028938A1
(en)
*
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
AU2010313324A1
(en)
*
|
2009-10-30 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
AX213 and AX132 PCSK9 antagonists and variants
|
|
JO3756B1
(ar)
*
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
CA2825778A1
(en)
*
|
2011-01-28 |
2012-08-02 |
Sanofi |
Pharmaceutical compositions comprising human antibodies to pcsk9
|
|
JOP20200043A1
(ar)
*
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
US20140004122A1
(en)
*
|
2011-05-10 |
2014-01-02 |
Amgen Inc. |
Methods for treating or preventing cholesterol related disorders
|
|
ITPN20110039A1
(it)
*
|
2011-05-24 |
2012-11-25 |
Keyline S P A |
Blocchetto di presa perfezionato per macchina duplicatrice di chiavi
|
|
AR087305A1
(es)
*
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
EA039663B1
(ru)
*
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
US9255154B2
(en)
*
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
WO2013170367A1
(en)
*
|
2012-05-17 |
2013-11-21 |
The University Of British Columbia |
Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors
|
|
AR091462A1
(es)
*
|
2012-06-15 |
2015-02-04 |
Genentech Inc |
Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
|
|
US20150335615A1
(en)
*
|
2013-01-04 |
2015-11-26 |
Toshihisa Kawai |
Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
|
|
WO2014145744A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Alder Biopharmaceuticals, Inc. |
Antibody purification and purity monitoring
|
|
AU2014235430A1
(en)
*
|
2013-03-15 |
2015-09-24 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
|
TW201534324A
(zh)
*
|
2013-06-07 |
2015-09-16 |
Sanofi Sa |
藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
|
|
JP6267792B2
(ja)
*
|
2013-06-28 |
2018-01-24 |
アムジエン・インコーポレーテツド |
ホモ接合性家族性高コレステロール血症の治療方法
|
|
US20150004174A1
(en)
*
|
2013-06-28 |
2015-01-01 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
MX373298B
(es)
*
|
2013-10-11 |
2020-05-20 |
Sanofi Biotechnology |
Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
|
|
US10428157B2
(en)
*
|
2013-11-12 |
2019-10-01 |
Sanofi Biotechnology |
Dosing regimens for use with PCSK9 inhibitors
|
|
US8883157B1
(en)
*
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9023359B1
(en)
*
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9034332B1
(en)
*
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
EA201691320A1
(ru)
*
|
2014-02-14 |
2016-11-30 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
|
|
BR112016017402A2
(pt)
*
|
2014-02-21 |
2017-10-17 |
Medimmune Ltd |
fusões anti-pcsk9~glp-1 e métodos para uso
|
|
CN114558129A
(zh)
*
|
2014-03-17 |
2022-05-31 |
赛诺菲生物技术公司 |
用于降低心血管风险的方法
|
|
US20150283236A1
(en)
*
|
2014-03-17 |
2015-10-08 |
Marie Baccara-Dinet |
Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
|
|
CA2954773C
(en)
*
|
2014-07-14 |
2023-10-03 |
Amgen Inc. |
Crystalline antibody formulations
|
|
US20170198059A1
(en)
*
|
2014-07-14 |
2017-07-13 |
Amgen Inc. |
Crystalline antibody formulations
|
|
KR20230074283A
(ko)
*
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
EP3197492A1
(en)
*
|
2014-09-23 |
2017-08-02 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
|
EP3439715B1
(en)
*
|
2016-04-08 |
2021-03-10 |
Amgen Inc. |
Drug delivery device
|
|
US11596699B2
(en)
*
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
|
IL307684B2
(en)
*
|
2016-09-29 |
2025-04-01 |
Amgen Inc |
Low viscosity antigen binding proteins and methods for preparing them
|
|
JP7275027B2
(ja)
*
|
2016-10-06 |
2023-05-17 |
アムジェン インコーポレイテッド |
粘度低下タンパク質医薬製剤
|
|
JOP20190112A1
(ar)
*
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
US20190031774A1
(en)
*
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
|
KR20200067195A
(ko)
*
|
2017-10-18 |
2020-06-11 |
리젠엑스바이오 인크. |
완전-인간 번역후 변형된 항체 치료제
|
|
WO2020014143A1
(en)
*
|
2018-07-08 |
2020-01-16 |
Specifica Inc. |
Antibody libraries with maximized antibody developability characteristics
|